$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000119312512355553 Filed on August 14, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q2
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.090M	$1.770M	$30.00K
YoY Change	2351.52%	5800.0%
% of Gross Profit
Research & Development	$17.78M	$13.01M	$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization	$70.00K	$70.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$25.87M	$14.78M	$34.27K
YoY Change	7647.94%	43025.64%
Operating Profit	-$25.87M	-$14.78M	-$34.27K
YoY Change	7647.94%	43025.64%
Interest Expense	$10.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$14.00K	$23.00K
YoY Change	-203.7%
Pretax Income	-$25.86M	-$14.75M	-$30.00K
YoY Change	7288.57%	49066.67%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$25.86M	-$14.75M	-$34.27K
YoY Change	7342.85%	42958.51%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.290M	-$736.0K	-$7.500K
COMMON SHARES
Basic Shares Outstanding	20.04M shares	20.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.30M	$41.00M
YoY Change
Cash & Equivalents	$33.35M	$41.00M
Short-Term Investments
Other Short-Term Assets	$800.0K	$800.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.12M	$41.83M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$1.169M	$1.228M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.200M	$1.400M
YoY Change
Total Long-Term Assets	$2.381M	$2.608M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$34.12M	$41.83M
Total Long-Term Assets	$2.381M	$2.608M
Total Assets	$36.50M	$44.44M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.018M	$2.410M
YoY Change	409.03%
Accrued Expenses	$25.64M	$13.13M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.66M	$15.54M
YoY Change	6564.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$800.0K	$900.0K
YoY Change
Total Long-Term Liabilities	$800.0K	$900.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.66M	$15.54M
Total Long-Term Liabilities	$800.0K	$900.0K
Total Liabilities	$27.49M	$16.40M
YoY Change	6773.68%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$71.68M	$64.86M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.003M	$28.04M
YoY Change
Total Liabilities & Shareholders Equity	$36.50M	$44.44M
YoY Change

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$25.86M	-$14.75M	-$34.27K
YoY Change	7342.85%	42958.51%
Depreciation, Depletion And Amortization	$70.00K	$70.00K	$0.00
YoY Change
Cash From Operating Activities	-$7.640M	-$8.774M	-$40.00K
YoY Change	5357.14%	21835.95%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$240.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$160.0K	$0.00
YoY Change
Cash From Investing Activities	-$10.00K	-$400.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	40.00K
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-7.640M	-8.774M	-40.00K
Cash From Investing Activities	-10.00K	-400.0K	0.000
Cash From Financing Activities	0.000	0.000	40.00K
Net Change In Cash	-7.650M	-8.774M	0.000
YoY Change	-25600.0%
FREE CASH FLOW
Cash From Operating Activities	-$7.640M	-$8.774M	-$40.00K
Capital Expenditures	-$10.00K	-$240.0K	$0.00
Free Cash Flow	-$7.630M	-$8.534M	-$40.00K
YoY Change	5350.0%	21235.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20040000	shares
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	157000
CY2012Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	150000
CY2012Q2	ck0001401667	Lease Agreement Monthly Payment LeaseAgreementMonthlyPayment	20250
CY2011Q3	ck0001401667	Merger Stock Conversion Ratio MergerStockConversionRatio	1	pure
CY2011Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6900000
CY2011Q4	ck0001401667	Number Of Investors NumberOfInvestors	27	Entity
CY2011Q4	ck0001401667	Class Of Warrant Or Right Term ClassOfWarrantOrRightTerm	P10Y
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	825966
CY2012Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10751011
CY2012Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64857524
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	28038843
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3669475
CY2012Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15834
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1210176
CY2012Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	975607
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20040000	shares
CY2012Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	91104
CY2012Q2	us-gaap	Liabilities Liabilities	16397586
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2410026
CY2012Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	39720000
CY2012Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	36820685
CY2012Q2	us-gaap	Assets Assets	44436429
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
CY2012Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	170250
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44436429
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41001998
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20040000	shares
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13131701
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15541727
CY2012Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7371000
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1392500	shares
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	2004
CY2012Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	855859
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q2	us-gaap	Assets Current AssetsCurrent	41827964
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1228039
CY2012Q2	ck0001401667	Accrued Preclinical And Clinical Costs AccruedPreclinicalAndClinicalCosts	1298145
CY2012Q2	ck0001401667	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	1392500	shares
CY2012Q2	ck0001401667	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	4.97
CY2012Q2	ck0001401667	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	281096
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64610340
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	54372535
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41551
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1053284
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	308936
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20040000	shares
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	149055
CY2011Q4	us-gaap	Liabilities Liabilities	1025632
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	86669
CY2011Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	10239809
CY2011Q4	us-gaap	Assets Assets	55398167
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55398167
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53381734
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20040000	shares
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	499542
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	586211
CY2011Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7600000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	2004
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	439421
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Assets Current AssetsCurrent	53662830
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	682053
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	6531
	us-gaap	Net Income Loss NetIncomeLoss	-6931
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38206
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.010
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	168
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39935
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3363
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3363
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38038
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43298
	us-gaap	Operating Expenses OperatingExpenses	38206
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	43298
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4000000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-38206
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38206
	ck0001401667	Increase Decrease In Prepaid Expense And Other Assets IncreaseDecreaseInPrepaidExpenseAndOtherAssets	1897
	dei	Entity Registrant Name EntityRegistrantName	PUMA BIOTECHNOLOGY, INC.
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001401667
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26629028
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-236533
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	-214591
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	461775
	us-gaap	Share Based Compensation ShareBasedCompensation	461775
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14955516
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	156892
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.326
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Risk:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company’s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limit at June 30, 2012 were approximately $39,720,000. The Company does not believe it is exposed to any significant credit risk.</font></p> </div>
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	118236
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11558621
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-821115
	us-gaap	Investment Income Interest InvestmentIncomeInterest	48152
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	427690
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12379736
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2936503
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23574289
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-214591
	us-gaap	Operating Expenses OperatingExpenses	26629028
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M12D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461775
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	56500
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20040000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1392500	shares
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	236533
	us-gaap	Net Income Loss NetIncomeLoss	-26580876
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48152
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26580876
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include the valuation of the warrant issued to the Chief Executive Officer, or CEO (Note 4). The value of the warrant includes estimates based on future events which are difficult to predict. It is at least reasonably possible that a change in the estimates used to value the warrant will occur in the near term. Significant estimates also include the cost of services provided by consultants who conduct research on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period.</font></p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.30
	ck0001401667	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	179906
	ck0001401667	Increase Decrease In Prepaid Expense And Other Assets IncreaseDecreaseInPrepaidExpenseAndOtherAssets	715120
	ck0001401667	Lease Term LeaseTerm	P7Y
	ck0001401667	Lease Extension Period LeaseExtensionPeriod	P5Y
	ck0001401667	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P9Y8M12D
CY2011Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	40000
CY2011Q3	us-gaap	Payments For Merger Related Costs PaymentsForMergerRelatedCosts	40000
CY2011Q3	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1	18666733	shares
CY2011Q3	ck0001401667	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Shares Received NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentSharesReceived	18666733	shares
CY2011Q4	invest	Investment Warrants Expiration Date InvestmentWarrantsExpirationDate	2021-10-04
CY2011	us-gaap	Other Expenses OtherExpenses	80000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7585600
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67022
CY2011	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	61983
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-10232878
CY2011	ck0001401667	Issuance Of Common Stock In Exchange For Convertible Notes Value IssuanceOfCommonStockInExchangeForConvertibleNotesValue	150000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36792620
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-675954
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56741208
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-80000
	us-gaap	Share Based Compensation ShareBasedCompensation	528797
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15541727
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13390570
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2567154
	us-gaap	Investment Income Interest InvestmentIncomeInterest	51935
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	681024
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	41001998
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1210176
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	150000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	128938
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	150000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12263021
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24400661
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56959722
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	7371009
	us-gaap	Operating Expenses OperatingExpenses	36792620
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	68514
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	675954
	us-gaap	Net Income Loss NetIncomeLoss	-36820685
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28065
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36820685
	ck0001401667	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	179906
	ck0001401667	Increase Decrease In Prepaid Expense And Other Assets IncreaseDecreaseInPrepaidExpenseAndOtherAssets	996216
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-34265
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.009
CY2011Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	168
CY2011Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34097
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	34265
CY2011Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4000000	shares
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-34265
CY2011Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34265
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14777279
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.740
CY2012Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69495
CY2012Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8774379
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	22516
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1701877
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13005907
CY2012Q2	us-gaap	Equity Issuance Dates EquityIssuanceDates	2012-04-18
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	14777279
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	263715
CY2012Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	36000
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20040000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1392500	shares
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-14754763
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22516
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14754763
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.59

Files In Submission

Name	View Source	Status
0001193125-12-355553-index-headers.html	Edgar Link	pending
0001193125-12-355553-index.html	Edgar Link	pending
0001193125-12-355553.txt	Edgar Link	pending
0001193125-12-355553-xbrl.zip	Edgar Link	pending
ck0001401667-20120630.xml	Edgar Link	completed
ck0001401667-20120630.xsd	Edgar Link	pending
ck0001401667-20120630_cal.xml	Edgar Link	unprocessable
ck0001401667-20120630_def.xml	Edgar Link	unprocessable
ck0001401667-20120630_lab.xml	Edgar Link	unprocessable
ck0001401667-20120630_pre.xml	Edgar Link	unprocessable
d355276d10q.htm	Edgar Link	pending
d355276dex311.htm	Edgar Link	pending
d355276dex312.htm	Edgar Link	pending
d355276dex321.htm	Edgar Link	pending
d355276dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2012 Q3 Form 10-Q Financial Statement

#000119312512355553 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2012 Q3 Form 10-Q Financial Statement

#000119312512355553 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi